The use of Helium in acute myocardial infarction trial (HAMI-trial).
- Conditions
- Acute myocardial infarctionacute coronary syndromeischemia reperfusion injuryacuut hartinfarctacuut coronair syndroomischemie reperfusie schade
Recruitment & Eligibility
- Status
- Pending
- Sex
- Not specified
- Target Recruitment
- 70
Inclusion Criteria
1. Age 18-75 years;
2. ST-elevation myocardial infarction;
Exclusion Criteria
1. Left bundle branch block;
2. Previous myocardial infarction;
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method On day 4 after the PCI a CMR will be obtained. T-2 weighed imaging shows edema in the tissue which has been ischemic before and is therefore at risk for developing infarction. T-1 weighed imaging after the injection of gadolinium contrast marks the infarcted tissue. Primary endpoint is the total volume of infarction as proportion of the total volume of myocardium at risk.
- Secondary Outcome Measures
Name Time Method CMR measurements:<br /><br>1. On day 2-4: Left ventricular function, left ventricular dimensions, infarct size, edema;<br /><br>2. After 4 months: Left ventricular function, left ventricular dimensions, infarct size;<br /><br>3. Biomarker release following the PCI: Troponin T, NT-proBNP;<br /><br>4. Time of ST-segment resolution after opening of the target vessel;<br /><br>5. Thrombolysis in myocardial infarction (TIMI);<br /><br>6. Grade Flow following opening of the target vessel;<br /><br>7. Occurrence of death, re-infarction and admission for heart failure at 30 days and 4 months following PCI;<br /><br>8. New York heart Association functional class at 30 days and 4 months following PCI.